[July 1, 2025] Plumino Precision Fermentation Holdings Pte. Ltd. (hereinafter the “Plumino Group”), an emerging synthetic biology platform with deep industrial expertise in microbial fermentation and a strategic focus on pharmaceutical ingredients and nutritional health solutions, today announced the successful completion of its acquisition of the amino acids and Human Milk Oligosaccharides (“HMOs”) businesses of Kyowa Hakko Bio Co., Ltd. (hereinafter “Kyowa Hakko Bio”).
Following the acquisition, the Plumino Group will:
· Preserve Kyowa Hakko Bio’s legacy in industrial fermentation, carry forward its tradition of excellence in product quality, and remain committed to supporting customers of the acquired businesses.
· Strengthen its global position within the high-purity active pharmaceutical ingredients (APIs) and nutritional ingredients sectors; and expand the application of HMOs in premium nutrition markets.
Looking ahead, the Plumino Group will continue to invest in technological innovation and capacity enhancement to deliver superior solutions to its global customers. By combining the acquired business’ proven industrial fermentation expertise with the Plumino Group’s capabilities in synthetic biology, the Group aims to build one of the world’s most advanced precision fermentation platforms for health and nutrition ingredients.
Contact information for this matter：
Contact Number: +86 316 235 9999
Email address: wen.si@plumino.com